key: cord-0079176-uyxldpjf
authors: Li, Jiaqi; Jia, Huimin; Tian, Miaomiao; Wu, Nijin; Yang, Xia; Qi, Jianni; Ren, Wanhua; Li, Feifei; Bian, Hongjun
title: SARS-CoV-2 and Emerging Variants: Unmasking Structure, Function, Infection, and Immune Escape Mechanisms
date: 2022-05-12
journal: Front Cell Infect Microbiol
DOI: 10.3389/fcimb.2022.869832
sha: 1b9253c52e02d0a833ffaa10bf95313e90464f4a
doc_id: 79176
cord_uid: uyxldpjf

As of April 1, 2022, over 468 million COVID-19 cases and over 6 million deaths have been confirmed globally. Unlike the common coronavirus, SARS-CoV-2 has highly contagious and attracted a high level of concern worldwide. Through the analysis of SARS-CoV-2 structural, non-structural, and accessory proteins, we can gain a deeper understanding of structure-function relationships, viral infection mechanisms, and viable strategies for antiviral therapy. Angiotensin-converting enzyme 2 (ACE2) is the first widely acknowledged SARS-CoV-2 receptor, but researches have shown that there are additional co-receptors that can facilitate the entry of SARS-CoV-2 to infect humans. We have performed an in-depth review of published papers, searching for co-receptors or other auxiliary membrane proteins that enhance viral infection, and analyzing pertinent pathogenic mechanisms. The genome, and especially the spike gene, undergoes mutations at an abnormally high frequency during virus replication and/or when it is transmitted from one individual to another. We summarized the main mutant strains currently circulating global, and elaborated the structural feature for increased infectivity and immune evasion of variants. Meanwhile, the principal purpose of the review is to update information on the COVID-19 outbreak. Many countries have novel findings on the early stage of the epidemic, and accruing evidence has rewritten the timeline of the outbreak, triggering new thinking about the origin and spread of COVID-19. It is anticipated that this can provide further insights for future research and global epidemic prevention and control.

Coronaviruses are genotypically divided into four genera (alpha, beta, gamma, and delta) (Woo et al., 2010) , of which aand b-coronavirus can be major human pathogens by crossing the animalhuman barrier (Cui et al., 2019) . Up to the present, there are seven known species of human coronaviruses: 229E (a-CoV), NL63 (a-CoV), OC43 (b-CoV), HKU1 (b-CoV), MERS-CoV (b-CoV) , SARS-CoV (b-CoV) , and SARS-CoV-2 (b-CoV) (Qiang et al., 2020) . Specifically, SARS-of SARS-CoV-2 demonstrates that the initial COVID-19 outbreak on the west coast of the United States was mainly derived from Chinese isolates, while the pandemic in New York and the east coast of the US came from European isolates .

In Europe, the first confirmed case had contact with parents from Wuhan (Böhmer et al., 2020) . The patient was reported to be infected with SARS-CoV-2 on Jan 26 which resulted in 16 subsequent cases of infection (Böhmer et al., 2020) . Despite the implementation of multiple control measures, the epidemic continued to spread across Europe and North America and reached Africa (Egypt) on February 13, 2020. As for sub-Saharan Africa, the first confirmed case appeared in Nigeria (Giandhari et al., 2020) . As the last continent where the pandemic spread, South America confirmed its first case on February 25, 2020. By then, no continent in the world was spared (Elizondo et al., 2021) .

As the research continues to deepen, although the exact origin remains debatable, there is some small but increasing evidence regarding the source of this outbreak. Recently, many countries have made some discoveries about the early COVID-19 epidemic, and the continuous emergence of earlier cases has triggered deeper reflections on the origin and spread of the virus, which may rewrite the global timeline of the COVID-19 epidemic.

Outside of China, Italy was the first European country to be very strongly impacted by COVID-19 with the first autochthonous case identified in Lombardy on February, 21st, 2020 (Onder et al., 2020) . Based on the complete genomic characteristics and phylogenetic analysis, SARS-CoV-2 emerged in Northern Italy a few weeks before the first case was reported. In a previous study, as early as mid-December 2019, environmental surveillance has unambiguously demonstrated that SARS-CoV-2 is present in untreated wastewater of the Milan area, and its concentration is the same as that of samples collected in the later stages of the pandemic (La Rosa et al., 2021) . In addition, an oropharyngeal swab sample collected on December 5, 2019, suggested that a 4-year-old boy with no travel history in the Milan area tested positive for SARS-CoV-2, which was 3 months earlier than Italy's first reported case (Amendola et al., 2021) . After that, an international research team led by the University of Milan in Italy reported that they found the new coronavirus gene sequence in a biopsy sample from a young female dermatologic patient on November 10, 2019 (Gianotti et al., 2021) . This result advanced the appearance of the Italian "Patient Zero" from January 30, 2020 to November 2019. This finding is of considerable epidemiological significance as it substantially enhances our understanding of time and the map of the SARS-CoV-2 transmission routes.

Accumulating evidence has proved that in December 2019 the virus has spread throughout Europe and was misdiagnosed as cases of influenza (Deslandes et al., 2020) . According to research, in many areas where wastewater has been sampled, including France (Paris), Spain (Murcia), and three cities and regions in northern Italy (Milan/Lombardy, Turin/Piedmont, and Bologna/ Emilia Romagna), SARS-CoV-2 RNA has been detected in the effluent before the local government announced the first case of COVID-19, reflecting that the possible presence of large numbers of asymptomatic carriers and symptomatic patients who were shedding viral RNA prior to the first reported case (Randazzo et al., 2020; La Rosa et al., 2021) . A French study has proved the fact through retrospective analysis, and a French with no aetiological diagnosis for hemoptysis tested positive for SARS-CoV-2 (Deslandes et al., 2020) . The patient was hospitalized on 27 December 2019 and presented clinical features and radiological patterns frequently observed in Chinese and Italian cohorts previously, indicating that the virus was already spreading throughout the French population in late December 2019 owning to the lack of recent foreign travel (Deslandes et al., 2020) .

In accordance with the recent SARS-CoV-2 genome diversity analysis results, all sequences as of the end of 2019 shared a common ancestor and the virus has existed in the human host for a considerable time before it was identified (van Dorp et al., 2020) .

As we all know, respiratory droplets and direct contact are the main pathways of SARS-CoV-2 transmission. In common with other CoVs and influenza, SARS-CoV-2 can cause infection by invading mucosa of the eyes, nose, or mouth when infected persons cough or sneeze. Previous work has demonstrated that aerosol and fecal-oral routes also transmit SARS-CoV-2 . Based on evidence that the SARS-CoV-2 virus could remain viable in an aerosol for at least 3 hours in a closed environment (van Doremalen et al., 2020) .

Although the precise mechanism of SARS-CoV-2 transmission is still unclear, with the deepening of research, other transmission routes have been hypothesized. There is growing evidence that, though extremely rare, vertical transmission in utero is possible and its underlying mechanism is possibly correlated to the transmission of the well-known SARS-CoV-2-related inflammatory status to the fetus (Fenizia et al., 2020) . A recently published study has also shown that SARS-CoV-2 may not be transmitted during childbirth, as it was not detected in vaginal secretion, breastmilk, neonatal throat swab, umbilical cord blood, and amniotic fluid of pregnant women (Mohseni et al., 2020) . However, due to the upregulation of the ACE2 receptor expression, the fetal liver can be a target organ for SARS-CoV-2 infection during pregnancy (Mohseni et al., 2020) . Therefore, the effect on the placenta and the intrauterine vertical transmission potential of SARS-CoV-2 need to be further carefully explored, and its adverse consequence for maternal and infant should not be underestimated. In addition, body fluids are risk factors for viruses to invade the body (Mohseni et al., 2020) .

The full-length genome of SARS-CoV-2 is 30 kb, including the 5′-region encoding for non-structural proteins and the 3′-region encoding for structural proteins. It has 14 open reading frames (ORFs) coding for 27 proteins: structural proteins, nonstructural proteins, and accessory proteins (Hatmal et al., 2020) .

Transformation of the virus begins with the expression of ORF1a and ORF1b gene segments. ORF1a and ORF1b are encoded by the replicase gene and further translated into two large polyproteins (pp1a and pp1ab) (Plant and Dinman, 2008) . The ORF1a gene encodes for pp1a protein, while ORF1b forms a fusion protein pp1a/b with pp1a through ribosomal frameshifting (Plant and Dinman, 2008) . The processing products of pp1a are termed NSP1-NSP11, while NSP1-NSP10 and NSP12-NSP16 are processed products of pp1ab ( Figure 1) .

The translation frameshift site is a prominent feature of coronaviruses. It has been proposed that programmed ribosomal frameshifting, a crucial mechanism for regulation of ORF1b expression in coronaviruses, may depend on ribosome pausing (Lopinski et al., 2000) . The slippery sequence (UUUAAAC) and a downstream hairpin-type pseudoknot help express proteins by causing a deformation of the reading frames (Bakhshandeh et al., 2021) . Recently, it has been shown that the -PRRA-insertion sequence thought to be a translational pause site may be involved in the occurrence of stop codons (Postnikova et al., 2021) . It has also been demonstrated that codon usage bias, which plays an important role in efficient RNA translation, determines programmed ribosomal frameshifting and ribosome pausing (Postnikova et al., 2021) . Insertion of the furin site may be associated with the enhanced infectivity of SARS-CoV-2. This overlapping translation pausing is also strong evidence for the punctuated mode of evolution (Gould, 1994; Heasley et al., 2021) . Furthermore, there are two variants (-HRRA-and -LRRA-), whose functional mechanism is not yet clear, that have recently been identified (Postnikova et al., 2021) . Some believe that the -HRRA-probably impact infection and pathogenesis of the virus . Nevertheless, even furin's overall impact on infectivity has recently been questioned, so this remains somewhat controversial (Papa et al., 2021; Johnson et al., 2021) . Besides, since the frequency of the variant codon usage was not significantly altered, they may not drastically diminish the translation of the inserted sequence (Postnikova et al., 2021) . Of course, it cannot be ruled out that other differences in the variants may affect the pathogenicity of the virus.

Structural proteins provide the structural elements of viral particles, while nonstructural proteins have a multi-faceted role in viral replication, transcription, morphogenesis, and evasion of host antiviral immune responses (Majumdar and Niyogi, 2021) . Assembly of the replication-transcription complex (RTC) for cytoplasmic and membrane protection is pivotal to the formation of the new virus in host cells. Nsp3, one of the components of RTC, can be cleaved by PL protease to promote cytokine expression and suppress the host's innate immune response (Bakhshandeh et al., 2021) .

SARS-CoV-2 relies on RdRp, the central component of the replication/transcription mechanism, to replicate its genome, rather than host polymerase (Subissi et al., 2014; . The NSP12 catalytic subunit, along with its auxiliary factors NSP7 and NSP8, constitutes the SARS-CoV-2 RdRp complex (Subissi et al., 2014) . NSP12 can recognize templates, catalyze and extend nucleotide chains. The heterodimer composed of NSP7 and NSP8 acts as a cofactor not only to stabilize the complex but also to stimulate the enzymatic activity of NSP12 and enhance its binding to RNA. The second subunit of NSP8 is thought to play a role in extending the RNA template binding surface (Subissi et al., 2014; Zeng et al., 2021) . Nucleotide incorporation errors caused by RdRp can be corrected by NSP14 (ExoN), a proofreading exonuclease, to improve the fidelity of RNA synthesis (Subissi et al., 2014) .

Strains with RdRp mutations have been reported to have a 3fold higher mutation rate than strains without RdRp mutations (Zeng et al., 2021) . The mutation changes the hydrophobicity of the RdRp binding pocket, which may also be one of the reasons for the poor efficacy of remdesivir (Zeng et al., 2021) .

As with all coronavirus, SARS-CoV-2 encodes four structural proteins which are the spike, envelope, matrix, and nucleocapsid ( Figure 1 ). Despite the high structural similarity, the S protein of SARS-CoV-2 has a 10-20 folds stronger affinity for ACE2 than SARS-CoV, indicating that SARS-CoV-2 possesses more invasive ability . The structure of SARS-CoV-2 by cryo-EM has demonstrated that, like SARS-CoV, the spike protein of SARS-CoV-2 is also extensively glycosylated (Watanabe et al., 2020) . Spike protein (150 kDa) is a class I fusion protein. It is a large inactive precursor composed of 1273 amino acids and exists as a trimer on the surface of virion and has a characteristic crown-like appearance. The S protein is further processed into receptor-binding subunit S1 and membrane-fusion subunit S2, which have different functions respectively (Heald-Sargent and Gallagher, 2012) . The S1 subunit consists of the signal sequence, N-terminal domain (NTD), and receptor binding domain (RBD) (Figure 1) , where the receptor binding motif (RBM) binds to the ACE2 receptor to enter into the host cell (Shang et al., 2020) . Furthermore, the binding can also lead to a conformational change in S2 subunit from a pre-fusion to a postfusion state (Sainz et al., 2005) . These changes favor the exposure and activation of the S2 domain "fusion peptide" which further promotes the fusion of viral and host cell membrane, thus initiating the process of endocytosis Madu et al., 2009 ).

As stated earlier, the S-protein contributes to the entry of the virus inside the host cell while E-protein (8-12 kDa) is an integral transmembrane protein involved in virus assembly, budding, morphogenesis, and trafficking (Schoeman and Fielding, 2019) . It is composed of three domains: a 7-12 amino acid short hydrophilic NTD, a 25 amino acid long hydrophobic transmembrane domain, and a lengthy hydrophilic C terminal region (Sarkar and Saha, 2020) . Due to the ion channel activity of the hydrophobic domain, E protein also acts as a viroporin to facilitate viral release, in turn, pathogenicity (Nieto-Torres et al., 2014) . By changing the ion homeostasis of cellular organelles, viroporins complete production, maturation, and release processes of the virus (Nieva et al., 2012) . Noteworthy, according to the E protein sequence alignment, unlike SARS-CoV, the amino acid residue of SARS-CoV-2 at position 69 replaces the negatively charged glutamic acid with the positively charged arginine (Yoshimoto, 2020) . We speculate that the substitution of positively charged basic amino acids for negatively charged acidic amino acids here may be associated with mutations that increase fitness and decrease virulence .The effect of this amino acid substitution on host range and immune evasion remains unknown.Besides, more research is required to further clarify whether this substitution affects the structure, function, and stability of E protein.

M protein (25-30 kDa) is the most abundant structural protein in the CoVs family, with three transmembrane domains that play critical roles in virion formation and complex stabilization during virion assembly by binding of a short glycosylated Nterminal portion of M protein to Nucleocapsid protein (Arndt et al., 2010) . M protein gives the virus its spherical virion structure. In addition, research on a variety of CoVs revealed that the viral size is determined by the interaction of M protein with S, N proteins, and viral genomic RNA (Neuman et al., 2011) . The M-protein is more abundant in coronaviruses than the E and S proteins, and it is conserved among b-coronaviruses (Ye and Hogue, 2007) . Because of its interactions with all other structural proteins, the M protein is thought to be the fundamental organizer of viral assembly (Nieto-Torres et al., 2014) . Interestingly, on the one hand, the interaction between M protein and S protein is needed for S protein retention in the ER-Golgi intermediate compartment and incorporation into new virions (Opstelten et al., 1995) . M protein, on the other hand, is required for the intracellular production of viral particles that lack S protein. Coronavirus produces noninfectious virion with M protein but no S protein when Tunicamycin is present (Mousavizadeh and Ghasemi, 2021) . Additionally, M-protein also appears to alter immune responses by blocking nuclear factor kappa B (NF-kB), resulting in viral multiplication (Fang et al., 2007) . However, this theory is controversial. A recent study has demonstrated that the M protein of SARS-CoV-2, along with ORF3a, ORF7a, and N proteins, are considered NF-kB activators and do not directly inhibit or stimulate the IFN response (Su et al., 2021) .

Nucleocapsid protein (N protein) is essential for the integration and packaging of viral genomic RNA into virions. It has multiple functions including RNA synthesis control, RNA packaging in helical nucleocapsids, and cooperating with the M protein to assemble virions (McBride et al., 2014) . The gene of N protein is conserved and stable with little change over time, with 91 percent and 50 percent sequence identities to SARS-CoV and MERS-CoV, respectively (Hodge et al., 2021) . The S, M, E proteins are responsible for the viral coat's production, while the N protein is responsible for binding to the viral genome RNA and then condensing into a higher-order RNA-protein complex to initiate the assembly of virions, which is an essential step in the replication process of coronavirus.

In infected cells, N protein is produced in large amounts from sgRNA and is dynamically localized to the RTCs in the early stages of infection, where it promotes RNA template swapping and recruits host components to aid in the discontinuous transcription and translation of sgRNA (Verheije et al., 2010) . The completion of the above functions depends on the characteristic modular structure evolved by the N protein. Similar to SARS-CoV, the N protein of SARS-CoV-2 is a 46 kDa protein that contains two conserved folding domains (the Nterminal RNA binding domain and the C-terminal dimerization domain), flanked by three intrinsically disordered regions (IDRs) (Peng et al., 2020) . NTD mediates specific interactions with viral genome packaging signals, and CTD forms a compact dimer to facilitate vRNP assembly (Peng et al., 2020) . A conserved core IDR with a serine/arginine-rich region separates two domains (SR). The degree of phosphorylation in SR can realize different functions by affecting the physical properties of N + RNA condensates (Lu et al., 2021) .

RNA can trigger liquid-liquid phase separation (LLPS) of the N protein, which is a crucial step in viral assembly . Acidic environments have been proven to facilitate the triggering process, so adjusting pH may also be a feasible antiviral treatment direction . G3BP1 forms stress granules, which are an essential component of the host cell's antiviral response, and LLPS mediates their formation (Sanders et al., 2020) . The N protein interacts directly with colocalized G3BP1, possibly leading to sequestration of G3BP1, depletion of the cytoplasmic pool, and hindering the formation of stress granules to attenuate the stress response and evade the host innate immune response (Cubuk et al., 2021) . Alternatively, the N protein might boost viral replication by hijacking this protein or stress granules (Hou et al., 2017) . Additionally, the M protein can interact with N protein's C-terminal region to independently mediate phase separation of N protein and promote the assembly of condensates without RNA (Neuman et al., 2011; Lu et al., 2021) . RNA-mediated and M-mediated phase separation is achieved by forming condensates with distinct domains of the N protein (Lu et al., 2021) . Individual vRNPs are assembled along the genomic RNA to form the packaging (Lu et al., 2021) . Then the M protein interacts with these condensed RNPs and acts as an organizational hub for virion through a soluble CTD extending into the viral particle.

Taken together, proteins E, M, and N work together to assemble virions, whereas the S protein facilitates viral attachment, membrane fusion, and entrance (Mittal et al., 2020) .

Early research has demonstrated that both SARS-CoV-2 and SARS-CoV employ ACE2 as a cell entrance receptor . ACE2 is an integral membrane glycoprotein of type I that has a length of 805 amino acid residues (Jiang et al., 2014) . It contains an N-terminal peptidase domain and a C-terminal collectrin-like domain (Figure 2A ), ending with a 40 amino acid long single transmembrane intracellular segment . The C-terminal includes a transmembrane alpha-helix, while the N-terminal has one active site. There is also a signal peptide at the end of the N-terminal, in which the protein cleavage site is located next to it. As part of the reninangiotensin system (RAS), ACE2 cleaves Ang I into Ang 1-9, which is then processed into Ang 1-7 . Angiotensin-(1-7), as a ligand, binds to the G-protein-coupled receptor MAS, which elicits responses that can counteract those of the ACE/angiotensin II/AT1 axis and exerts actions of vasodilation, vascular protection, anti-fibrosis, antiproliferation, and anti-inflammation in multiple organs/ systems (Patel et al., 2017; Santos et al., 2018) . Moreover, ACE2 was found to have the functions of zinc metalloenzyme and carboxypeptidase on chromosome X (Beura et al., 2021) . As a result, because men have only one X chromosome, they have a higher fatality rate from SARS-CoV-2 infection than women .

After transcription, the N-terminal signal peptide is responsible for migration to the cell surface, while the Cterminal transmembrane domain is responsible for successful anchoring (Tipnis et al., 2000) . The tip of one of the two lobes of the N-terminal peptidase domain binds to the spike RBD to initiate infection .

Based on published findings, Neuropilin-1 is an important coreceptor for viral entry which allows SARS-CoV-2 and ACE2 to communicate more easily (Cantuti-Castelvetri et al., 2020) . Neuropilin-1 (NRP-1) and Neuropilin-2 (NRP-2) are two members of the Neuropilin family that have a profound impact on lymphangiogenesis, angiogenesis, and axon guidance (Schellenburg et al., 2017) . Both NRP-1 and NRP-2 are composed of five extracellular domains (a1/a2, b1/b2, and c domains), a single transmembrane (TM) stretch, and an intracellular PDZ domain-binding motif at C-terminal (Gu et al., 2002) ( Figure 2B ). Daly et al. showed that NRP-1 binds more strongly to the host cell surface than the S1 subunit, possibly destabilizing the S protein complex and activating the escape of S2 from the S1 subunit (Daly et al., 2020) . Notably, there is proof that NRP-1 promotes SARS-CoV-2 penetration into the central nervous system (Daly et al., 2020) . It has been suggested that this process may be through the olfactory epithelium of the nasal cavity, which perhaps explains the phenomenon of olfactory dysfunction seen in SARS-CoV-2 infected patients (Hopkins et al., 2021) . In addition, our research group has studied the contribution of NRP-1 in the occurrence and development of liver fibrosis, which may provide new insights into the mechanism of SARS-CoV-2 in liver injury .

AXL is a novel host receptor that not only enhances SARS-CoV-2 to enter human cells but also facilitates viral reproduction . It also known as Ark, UFO, or Tyro7, was originally a transforming gene isolated from human leukemia cells (O' et al., 1991) . As one of three receptor tyrosine kinases in the TAM family, it plays a key role in regulating cell growth, proliferation, apoptosis, and migration (Axelrod and Pienta, 2014) . AXL consists of two immunoglobulin (Ig)-like repeats and two fibronectin type III (FN III)-like repeats, a transmembrane domain, and an intracellular kinase domain (Linger et al., 2008) ( Figure 2C ). One of the unique features of the interaction between AXL and the SARS-CoV-2 S protein is that AXL interacts with the S protein NTD rather than RBD . Also, AXL is considered an ACE2independent receptor, given that it is not co-expressed with ACE2 in the human lung or trachea .

Vimentin is a type III intermediate filament protein that is widely expressed on the outer surface of mesenchymal cells, including endothelial cells, fibroblasts, macrophages, melanocytes, and lymphocytes (Lowery et al., 2015) . In human lung tissue, vimentin expression is high in lung endothelial cells, macrophages, T cells, and granulocytes, but low in type I and II alveolar cells and fibroblasts (Amraei et al., 2022) . Vimentin is a 53 kDa polypeptide of 466 amino acids consisting of a central a-helical rod domain flanked by non-a-helical N and C-terminal domains (head and tail) (Danielsson et al., 2018) . Its highly conserved a-helical rod domain has a Coil 1 motif near the Nterminus and a Coil 2 motif near the C-terminus ( Figure 2D ). Together, these molecules bind in parallel and align to form a coiled coil, which constitutes the basic structural building block of the entire filament protein family.

Endothelial cells have been recently identified as a direct target of SARS-CoV-2, and their damage can cause a transition from an anticoagulant to a procoagulant phenotype, resulting in microvascular thrombosis and severe coagulation disorders (Varga et al., 2020; . In addition, it is expressed in type II alveolar cells and nasal goblet secretory cells, which also express the known receptors ACE2 and TMPRSS2 (Ziegler et al., 2020; . Interestingly, a novel mechanism has recently been proposed by which cells that do not express vimentin can acquire vimentin from the extracellular environment through neutrophil NETosis, a program of neutrophil death that accompanies the formation of neutrophil extracellular traps (NETs) (Khandpur et al., 2013; Thiam et al., 2020; Suprewicz et al., 2022) . They also believe that vimentin may enable the SARS-CoV-2 virus to adhere to the cell surface, stimulate the cell membrane to wrap the virus, and thus initiate viral endocytosis (Suprewicz et al., 2022) . Previous work has shown that vimentin can act as an attachment factor or coreceptor for SARS-CoV-1, Japanese encephalitis virus, cowpea mosaic virus, human papilloma virus, and dengue virus (Koudelka et al., 2009; Das et al., 2011; Yu et al., 2016; Yang et al., 2016; Schäfer et al., 2017) . And it can directly interact with the S protein to enhance the entry of SARS-CoV during the binding process of the S protein to ACE2 (Yu et al., 2016) . Amraei et al. showed that vimentin can bind to the RBD of SARS-CoV-2 as an attachment factor to facilitate viral entry and infection of endothelial cells (Amraei et al., 2022) . Notably, different motifs on the RBD bind vimentin and ACE2 to improve ACE2-dependent viral entry, respectively (Amraei et al., 2022) . Vimentin filaments can be found in the cytoplasm and extracellular compartments, and they co-localize with ACE2 in the cell-cell contact area, acting as a link for spike-ACE2 binding (Amraei et al., 2022) .

In summary of earlier studies, vimentin plays important roles in viral infection and lung injury in the following ways: a. interacting with spike proteins to facilitate viral entry; b. influencing virus production during replication or assembly; c. participating in inflammatory and immune responses d. promoting endothelial mesenchymal transition and fibrosis . But its specific role in SARS-CoV-2 virus infection needs more research to confirm. However, anti-vimentin antibodies will certainly be an effective therapeutic strategy for SARS-CoV-2 by blocking the infection of variants or reducing clinical symptoms. Meanwhile, vimentin-coated viruses may bind and aggregate with anti-vimentin antibodies, thereby inhibiting viral infection and promoting viral clearance.

Besides all those mentioned above, there may be other receptors that mediate viral entry as research progresses. Several proteins that interact with SARS-CoV-2 S have been identified, including cellular heparan sulfate, sialic acids, CD147, and several C-type lectin receptors (DCL-SIGN, L-SIGN, MR, and MGL) (Clausen et al., 2020; Theṕaut et al., 2021; Sun, 2021) . Because heparin significantly affects the open conformation of RBD making it more susceptible to ACE2 binding, cellular heparan sulfate plays an important role as a potential receptor in ACE2-dependent SARS-CoV-2 infection (Clausen et al., 2020) . Sulfate and ACE2 binding sites on the RBD are next to each other, which provides the structural basis for this function (Clausen et al., 2020) . Furthermore, a receptor-overexpression and ligand-labeling system identified two additional potential candidate receptors, ASGR1 and KREMEN1, by screening more than 5000 human membrane proteins . They both interact with NTD and RBD, and KREMEN1 also interacts with the S2 domain. This diversity of receptor usage may explain why SARS-CoV-2 is more contagious than other coronaviruses.

The coronavirus spike protein is always subjected to proteolysis happens with the assistance of numerous protease activators when binding to host cell receptors and initiating subsequent plasma membrane fusion or endocytosis (Li, 2016) . In particular, viral fusion and entrance begin with exposure of the internal fusion peptide following proteolysis of the S protein . The fusion and entry process requires three categories of proteases that function at different stages of infection: (a) phase of viral attachment: proprotein convertases (e.g., furin), (b) phase of S1 cleavage and detachment from the S2 domain: cell surface proteases [e.g., type II transmembrane serine protease (TMPRSS2)] and (c) phase of intraviral endocytosis: lysosomal proteases (e.g., cathepsin B/L) . However, it should be pointed out that many extracellular proteases and many other host proteases may be involved in the cleavage of SARS-CoV-2 S protein based on the in vivo complexity and ubiquitous infection .

Furin is a calcium-dependent type I membrane-bound serine endoprotease enzyme that belongs to the seven-member family of subtilisin-like proprotein convertases (Thomas, 2002) . Its main job is to complete the activation process by cutting off biologically inactive portions of the protein (Ganesan et al., 2020) . SARS-CoV-2 inserts a polybasic residue (RRAR) at the junction of S1 and S2 cleavage sites, whereas SARS-CoV has only one basic amino acid (Amanat et al., 2021) . Thus, the spike of SARS-CoV isn't separated by proprotein convertases during virus particle formation and stays untouched on mature virions (Li, 2016) . SARS-CoV-related coronaviruses (SARSr-CoV) lack this particular multibasic cleavage site, but it is present in human coronaviruses HKU1, OC43, and MERS-CoV . Furin cuts S1/S2 site, granting the virus to infect host cells (Shiryaev et al., 2013) . Unlike the restricted expression of other endoserine proteases, furin is extensively distributed and is expressed to different extents in distinct tissues and organs throughout the body (Ganesan et al., 2020) . As a result, the almost ubiquitous expression of furin-like proteases may explain the high pathogenicity and severity, broad cell and tissue tropism, multiple organ damage as well as increasing its transmissibility of COVID-19 (Ganesan et al., 2020) . Moreover, the spike cleavability is thought to determine the zoonotic potential under coronavirus infection .

Recent studies have demonstrated that the addition of basic residues at the furin cleavage site in viral variants increases cellcell fusion but not virus-cell fusion . However, it should be mentioned that although the loss of furin significantly reduces infection by reducing the infectivity of virus particles rather than reducing virus production, it does not eliminate it (Papa et al., 2021) . As a result, there is no doubt that furin is an extremely critical cofactor, but it is not required for infection, and replication will proceed even without it (Papa et al., 2021) . This is also one of the reasons why existing antiviral treatments for SARS-CoV-2 based on furin-targeted medicines may not completely prevent viral infection (Papa et al., 2021) . In addition, considering that furin is essential for normal development, short-term inhibitor treatment might be welltolerated, but blocking this enzyme for a prolonged time might lead to unwanted toxic effects .

TMPRSS2 is a 492 amino acid residue long located on human chromosome 21q 22.3 (Antalis et al., 2011) . It contains four different domains: a type II transmembrane domain, an LDL receptor class A (LDLRA) domain, a scavenger receptor cysteinerich (SRCR) domain, and a serine protease domain (Thunders and Delahunt, 2020) ( Figure 2E ). To date, the physiological roles of TMPRSS2 are still not completely understood, but it is involved in a variety of biological processes (Thunders and Delahunt, 2020) .

Another important function of TMPRSS2 is to cleave and trim the spike proteins to produce a better conformational state, and further activate the S protein to expose its fusion region to achieve the aim of ACE2 binding activity and virus-cell fusion . It has been shown that TMPRSS2 expressing cells can isolate more SARS-CoV-2 virus particles than non-expressing cells (Matsuyama et al., 2020) . It is characterized by a highly conserved catalytic serine protease domain stabilized by three intradomain disulphide bonds (Brooke and Prischi, 2020) . The S1 domain contains the catalytic triad required for enzymatic activity, in analogy with the furin subtilisin-like domain (Brooke and Prischi, 2020) . The catalytic triad binding site forms a negatively charged pocket, which is conducive to electrostatic interactions with the positively charged peptides of the Spike to catalyze the cleavage, leading to the viral entry (Brooke and Prischi, 2020; Abbasi et al., 2021) . Unexpectedly, after the interaction of S protein with ACE2, TMPRSS2 cleaves at the arginine and lysine residues of ACE2, resulting inACE2 shedding and promoting viral particles uptake (Thunders and Delahunt, 2020) . In addition to fusion mediated by virions, spike protein present at the plasma membrane can trigger the formation of receptordependent syncytia, and TMPRSS2 accelerates this process (Buchrieser et al., 2020) . Furthermore, as an androgenregulated gene, it may be one of the reasons for these gender disparities in the severity of disease course which persists across nations (Chakravarty et al., 2020) . It is worth noting that loss of smell (anosmia), as one of the most prevalent and significant characteristics of COVID-19, may also be related to TMPRSS2 .

Indeed, it has been demonstrated that variants with loss of the TMPRSS2 cleavage site allow SARS-CoV-2 entry entirely via the endosome pathway and thus exhibit a more limited range of cell tropism (Lau et al., 2020; Sasaki et al., 2021) . Under powerful selective pressure, these variants may exist at very low levels in some infected individuals, and it is necessary to screen more clinical samples of patients with mild or asymptomatic infections (Lau et al., 2020) .

Two ways can be used by coronaviruses to enter host cells: In the early stage of entry, the direct fusion of the virus on the plasma membrane is mediated by TMPRSS2; while in the late entry pathway, the coronavirus can be internalized via cathepsinmediated endocytosis . Cathepsins are classified into three main categories: serine proteases cathepsins, aspartic proteases cathepsins, and lysosomal cysteine cathepsins (Tabrez et al., 2020) . Endo-and exopeptidase cathepsin B and endopeptidase cathepsin L that play a critical role in endocytosis are lysosomal cysteine proteases . The endoplasmic reticulum produces them, and the Golgi apparatus transports them to the lysosome and endosome . Low pH is required for their optimal enzymatic activity due to their subcellular location . Cathepsin B and Cathepsin L are known fusion activators that become active in early and late endosomes, respectively . Low endosome pH can activate cathepsin L to release the genome by triggering the fusion of virion membrane with endosome membrane . Evidence suggests that it is also cathepsin L, not cathepsin B, that plays a key role in the initiation of the S protein (Ou et al., 2020) . We believe that elevating endosomal pH to inhibit the activity of cathepsin B/L or simultaneously targeting TMPRSS2 and cathepsin B/L are both feasible therapeutic directions.

The lifecycle of SARS-CoV-2 commences by binding the S1 RBD to the peptidase domain of ACE2 (Figure 3) . Upon binding, furin cleaves S protein into the S1 and S2 subunits at the multibasic site, resulting in structural change in the S2 subunit (Walls et al., 2020) . TMPRSS2 cleavage at the S2 site further exposes the fusion peptide (Walls et al., 2020) . In the meantime, the S2 subunit's heptad repeat 1 and heptad repeat 2 domains combine to produce a six-helix bundle fusion core, which brings the virus particles close to the host cell membrane . Cathepsins can work independently on cells lacking TMPRSS2 and form endocytosis and low pH endosomes, hence mediating virus-cell membrane fusion at the cell surface and endosomal compartments, respectively (Sasaki et al., 2021) . Through either entry mechanism, the RNA genome is released into the cytosol, where it is translated into replicase protein and digested by chymotrypsin-like protease (3C-like protease or 3CL pro ) and papain-like protease through a complicated multistep process to produce 16 non-structural proteins (Baéz-Santos et al., 2015) (Figure 3) . RdRp catalyzes viral genome replication and subgenomic transcription to assemble new viral particles.

The formation of double-membrane vesicles (DMVs) in the host cell induced by SARS-CoV-2 infection, is the first step in replication. NSP3 and NSP4 drive the rearrangement of the endoplasmic reticulum (ER) into DMV and promote genomic RNA (gRNA) and subgenomic RNAs (sgRNAs) replication (Tabata et al., 2021) . The viral RNAs are stored in DMVs and transported to the cytosol for translation or through doublemembrane-spanning pores for viral assembly . Structural proteins package gRNA to build progeny virus particles, while the shorter sgRNAs encode conserved structural and accessory proteins. The cytoplasm is the site of RNA and N protein synthesis, while S, M, and E proteins are synthesized in the endoplasmic reticulum and removed to the Golgi apparatus ( Figure 3) . From there, the viral RNA-N complex and S, M, and E proteins follow the secretory pathway to reach the endoplasmic reticulum-Golgi intermediate compartment (ERGIC) to assemble mature virions. After that, the virus particles are released through the budding process of the Golgi apparatus and exocytosis of the cell membrane to start a new round of infection. S protein monomer is also extensively modified via Nglycosylation and trimerizes in the ERGIC. The glycosylation of viral proteins has a wide range of roles, including mediating protein folding, affecting viral stability, infectivity, and immune evasion.

Variants that are currently spreading rapidly around the world can be divided into variants of concern, variants of interest, and variants under monitoring (WHO, 2022b). All variants share one specific mutation called D614G which was the dominant variant early in the global epidemic. The D614G mutation occurs when aspartic acid is replaced with glycine at position 614 of the S protein (Jackson et al., 2021) . It was first detected in late January 2020, and began to emerge in March 2020, and continuously derived different clades (Jackson et al., 2021) . The D614G mutation promotes allosteric of the RBD domain to the "up" conformation bound to the receptor ACE2 by eliminating the hydrogen-bonding interaction with T859 of the adjacent protomer from the spike trimer, thereby enhancing virion infectivity and further enhancing the replication of SARS-CoV-2 in the upper respiratory tract . In addition, due to the presence of D614G in the SD2 domain, it also enhances furin cleavage at the S1/S2 domain junction (Mohammad et al., 2021) . However, the D614G proved to potentially reduce the binding affinity to ACE2 and possibly alter the predicted MHC binding, the biological significance of which warrants further investigation (Mohammad et al., 2021) .

Variants of concern (VOC) refer to VOI-defined variants with enhanced transmissibility, virulence, and poor response to current diagnostics, vaccines, and treatments (WHO, 2022b). The five variants of concern are alpha, beta, gamma, delta, and omicron.

Alpha (B.1.1.7 Lineage) B.1.1.7 lineage was circulating in Britain as early as September 2020 and was identified in America at the end of December 2020 (Cascella et al., 2021) . Seventeen mutations were identified in the Alpha variant genome. Among them, eight mutations (D69-70 deletion, D144 deletion, N501Y, A570D, P681H, T716I, S982A, D1118H) are in the spike protein. Amino acid changes in the B.1.1.7 protein improve both the accessibility of RBD and the affinity for ACE2, which might be one of the causes for the increased transmission (Cai et al., 2021) . This N501Y single mutation increases the affinity between RBD and ACE2 by~10fold . Studies have shown that the N501Y mutation disrupts the stability of the SARS-CoV-2 S protein in addition to increase transmission rates (Mohammad et al., 2021) . More seriously, however, individuals infected with the B.1.1.7 lineage variant have a significantly higher severity of disease and risk of death relative to those who infected with other variants (Challen et al., 2021) .

The beta variant was reported in South Africa during mid-December 2020 and triggered a second wave of infections in Nelson Mandela Bay . Beta variant has nine mutations (L18F, D80A, D215G, R246I, K417N, E484K, N501Y, D614G, and A701V) in the spike protein, of which three mutations (K417N, E484K, and N501Y) are found in RBD and enhance the affinity for the receptors (Cascella et al., 2021) . The E484K mutation was shown to significantly alter the electrostatic complementarity of antibody binding to RBD (Mohammad et al., 2021) . In comparison with the previous three largest lineages (B. 1.1.54, B.1.1.56 , and C.1) circulating in South Africa, B.1.351 shows remarkable hypermutation including nonsynonymous mutations that result in amino acid changes . The N501Y substitution has also been identified in rapidly spreading lineages (B. 1.1.7 and B.1.351) , and was the only shared mutation of RBD among the three variants, indicating that exert significant functions in transmission and epidemic (Cascella et al., 2021; Tegally et al., 2021) . Previous studies have shown that both N501Y substitution and E484K substitution may increase the affinity with human ACE2, and the combination of N501Y and E484K further enhances the affinity .

Notably, the P71L amino acid substitution was discovered in beta variant's E protein. And so far, no mutation of the E protein has been reported in all SARS-COV-2 variants except the Beta variant (Mohammad et al., 2021) . The mutation is known to be associated with disease severity and mortality, but its specific mechanism needs further study. Although the full import of the mutations remains unclear, the genomic and epidemiological data demonstrate that this variant has a selective advantage as a result of greater transmissibility, immune escape, or both .

The gamma variant was reported in December 2020 in Brazil and was first identified in America in January 2021 (Cascella et al., 2021) . The gamma variant includes ten mutations in the spike protein (L18F, T20N, P26S, D138Y, R190S, H655Y, T1027I V1176, K417T, E484K, and N501Y). Three mutations (L18F, K417N, E484K) are found in RBD, identical to the beta variant (Cascella et al., 2021) .

The fourth variant of concern, delta variant is also known as the B.1.617.2 was initially identified in December 2020 in India and was responsible for the deadly second wave of COVID-19 infections in April 2021 in India (Cascella et al., 2021) . In America, this variant was first reported in March 2021 and was reported to be more transmissible, surpassing preexisting variants of SARS-CoV-2 to emerge as the dominant SARS-CoV-2 variant in most countries (Cascella et al., 2021) . The delta variant harbors ten mutations (T19R, (G142D*), 156del, 157del, R158G, L452R, T478K, D614G, P681R, D950N) in the spike protein (Cascella et al., 2021) .

Omicron (B.1.1.529 Lineage)

The omicron variant, which has attracted the most global attention, was first reported in South Africa on November 23, 2021 and has been identified in over 100 countries and regions worldwide (Vaughan, 2021) . The next day, WHO listed it as Variants under monitoring (VUM). On November 26, according to the evaluation results of the Virus Evolution Working Group, WHO named it omicron and listed it in VOC (Ferréet al., 2021) . Preliminary data and analysis obtained locally show an exponential increase in the outbreak in South Africa, and in contrast to the prevalence of beta and delta variants, omicron reduces the risk of initial infection in the population but increases the risk of repeat infection (CDC, 2021). Omicron has more than 50 mutations, 30 of which are on the S protein on the surface of the virus. Among them, there are more than 20 new mutations in the S1 domain, 8 mutations are located in NTD and 15 mutations are located in RBD, which may directly enhance the interaction between RBD and ACE2 and avoid binding to antibodies induced by previous infection or vaccination (Ferréet al., 2021) . Mutations at the Flynn cleavage site may be linked to increased transmission (CoVariants, 2021) . In addition, the insertion sequence (ins214EPE), which appeared for the first time in SARS-CoV-2, was shown to be expressed in the common cold coronavirus (HCoV-229E). This may explain the cold-like symptoms and short incubation period of around 3 days caused by omicron . Remarkably, however, other symptoms caused by omicron, such as loss of smell and taste, are not present in common influenza. Moreover, the longterm stay of the virus in the body can penetrate various organs. Even after recovery, it can still reignite and attack the CNS, causing many infected people to die of sequelae. Therefore, omicron will still have a serious impact in the long run.

Interestingly, traces of the omicron virus were found in wastewater in New York City on November 21, according to the latest traceability study published by the CDC (2022). This was the day before South African scientists announced the confirmation of the omicron variant and ten days before the first omicron variant infection was reported in the United States. Also in California and Texas, researchers found evidence of omicron in wastewater samples in late November (CDC, 2022) . Besides, omicron variants have also been detected in wastewater treatment plants in France since mid-November (Ferréet al., 2021) . Although the existing evidence cannot lead to the conclusive conclusion that omicron existed in these places at the time, it still has implications for the discovery and transmission of the virus.

Variants of interest (VOI) are defined as variants with specific genetic markers that affect infectivity, disease severity, immune escape, diagnostic or therapeutic escape, and spread across multiple countries and regions causing serious damage. In the early stages, VOI consisted of eight variants, including Epsilon (B.1.427 and B.1.429); Zeta (P.2); Eta (B.1.525); Theta (P.3); Iota (B.1.526); Kappa (B.1.617.1); Lambda (C.37) and Mu (B.1.621) (Cascella et al., 2021) . The first six variants have been reclassified as they have finally proven to no longer pose a significant risk to global public health. Therefore, the current VOI only includes Lambda and Mu variants (WHO, 2022b) .

Variants under monitoring (VUM) are defined as a variant with genetic changes that may pose a risk in the future, requiring enhanced surveillance and repeated assessment (WHO, 2022b 

Under the severe situation of repeated outbreaks and the prevalence of new variants, there is still a lack of effective vaccines and antiviral treatments to control the spread of the epidemic, which is a huge challenge for us humans. A growing number of research based on the structure, function, infection mechanism and immunology of virus are pointing the way to the development of effective vaccines and specific drugs against variants in the future. Generally, antiviral therapy that inhibits the entry and replication of SARS-CoV-2 virus plays a significant role in the early stage of the disease; while in the later stage of the disease, when the immune/inflammatory response is enhanced, immunomodulatory and anti-inflammatory therapy may be more beneficial to patient's recovery.

The first step in the infection process is the attachment and entry of SARS-COV-2 into host cells, and blocking this process has critical implications for disease prevention and early treatment ( Figure 4A ). Blocking the S protein that binds to the receptor is essential for suppressing infection. At present, S protein inhibitors mainly include monoclonal antibodies, convalescent plasma, nanobodies, miniproteins, human soluble ACE2 and ACE2 receptor trap molecules (Rojas et al., 2020; Esparza et al., 2020; Cao et al., 2020; Monteil et al., 2020; Linsky et al., 2020; Corti et al., 2021) . For receptors, lactoferrin blocks the attachment of virus to the host cell by binding heparan sulfate, and can synergize with remdesivir to exert an anti-viral effect . As research progresses, more co-receptors are identified and are expected to become drug targets for COVID-19 therapy. Inhibitors of co-receptors and their generic particles, while in principle suppressing SARS-CoV-2 infection, still need to be validated in more clinical trials. SARS-CoV-2 enters host cells via receptor-mediated membrane fusion or the endosomal pathway. Host proteases (eg, furin, TMMPRS2) can promote S protein attachment and virus-cell membrane fusion, so their inhibitors are essential to block fusion entry of SARS-COV-2. Furin inhibitors (decanoyl-RVKR-chloromethylketone) and TMPRSS2 inhibitors (camostat mesylate, neformastat, antiandrogens, bromhexine) have been shown to have varying degrees of effect in reducing SARS-COV-2 infection (Zhou et al., 2015; Mollica et al., 2020; Ansarin et al., 2020; Cheng et al., 2020) . In addition, Catepsin L inhibitors (SSAA09E1, teicoplanin, K1777), hydroxychloroquine, umifenovir, nitazoxanide and niclosamide all exert antiviral effects through the endosomal entry pathway (Axfors et al., 2021; Simsȩk-Yavuz and Komsuoglu Çelikyurt, 2021; Huang et al., 2021; Lokhande and Devarajan, 2021; Backer et al., 2021) .

After viral entry, inhibition of viral replication by inhibiting viral RNA and protein synthesis is another mechanism in antiviral therapy ( Figure 4B ). M pro and PL pro are attractive targets for drug development as proteases essential for viral replication. As M pro is highly conserved and has no human homologues, its inhibitors (lopinavir/ritonavir, PF-07321332, PF-07304814, GC376) are currently in various stages of preclinical and clinical development (Simsȩk-Yavuz and Komsuoglu Çelikyurt, 2021) . Inhibitors that inhibit RNA synthesis mainly include RdRp inhibitors (remdesivir, favipiravir, molnupiravir, AT-527), RNA synthesis-related host protein inhibitors (merimepodib and PTC299) and a gene-editing enzyme, Cas13a, that shreds RNA into pieces (Luban et al., 2020; Simsȩk-Yavuz and Komsuoglu Çelikyurt, 2021; Adegbola et al., 2021; Blanchard et al., 2021) . In contrast to targeting viral proteins, targeting host proteins has multiple advantages. Precisely, because of such a high rate of mutation of the virus, anti-viral drugs will quickly lose their effectiveness, but due to the relatively host low mutation rate, targeting the host protein is a more feasible therapeutic strategy (Azouz et al., 2020) . Host protein inhibitors that support viral protein synthesis including the eEF1A inhibitor (plitidepsin) and the ER chaperon protein inhibitor (fluvoxamine) exhibit potent antiviral activity (Simsȩk-Yavuz and Komsuoglu Çelikyurt, 2021). Of note, targeting human proteins is the potential risk of changing the physiological pathway. In conclusion, more study is required to definitively comprehend the specific effects of host proteins on the human body to guide the feasible direction offuture antiviral therapy.

Immune responses play a key role in disease process, and the immune escape mechanisms of SARS-COV-2 and variants are not fully understood. Immunomodulators such as ivermectin and interferon have demonstrated antiviral activity in a variety of viruses, but their therapeutic effects on COVID-19 are still controversial ( Figure 4C ) (Caly et al., 2020; Alavi Darazam et al., 2021) . Additionally, traditional Chinese medicine also has immunomodulatory effects, and can fight viruses independently or in synergy with Western medicine . Due to the lack of relevant studies, whether there are other antiviral mechanisms besides immune regulation remains to be further elucidated. Furthermore, in December 2021, China developed the first COVID-19 specific antibody drug, the combination therapy of , and approved for marketing. Clinical data show that the antibody can remain in the human body for 9 to 12 months. It is active against the main popular variants and plays a certain role in preventing infection. On March 14, 2022, the drug was included in the ninth edition of China's COVID-19 diagnosis and treatment plan.

In the near future, newly developed vaccines are also expected to protect against existing and emerging variants of SARS-CoV-2 ( Figure 4D ). According to statistics, as of March 2022, there are (Ling et al., 2021) . However, inactivated vaccines have the lowest incidence of adverse events, and the safety of mRNA vaccines and viral vector vaccines remains controversial.

Viral genomes have evolved due to mutations that allow them to adapt well to their hosts and reproduce continuously. They make the virus more infectious, transmissible and help evade the host's immune response by modifying the epitope of the gene. As the COVID-19 pandemic develops, a deeper study of those evolving SARS-CoV-2 variants is critical to understanding mutational adaptability and identifying control measures for the COVID-19 pandemic. A global survey of SARS-CoV-2 genes revealed that mutations in structural, nonstructural, accessory proteins, and untranslated regions were the most common (Majumdar and Niyogi, 2021) . Furthermore, mutations in ORF1a, ORF1b, N, and S proteins were present in almost all countries, with the least number of variants in M and E, indicating that they are conserved proteins (Majumdar and Niyogi, 2021) . Single nucleotide substitutions are the most common of the numerous forms of mutations. Additionally, insertions, deletions, and frameshift mutations have also been reported, albeit at lower frequencies.

Mutations can alter the antigenic properties of glycoproteins through a variety of different mechanisms, including increasing receptor binding affinity, deleting or inserting residues, altering epitope amino acid substitutions, glycosylation motifs, and protein conformation. Emerging SARS-CoV-2 variants share common features: increased virus transmissibility, infectivity, virulence, and antibody resistance from convalescent sera or vaccines, while also evolving the ability to immune escape. However, the emergence of attenuating mutations suggests an evolutionary trend toward reduced pathogenicity to achieve long-term coexistence with the host. Many scholars believe that the omicron variant is expected to end the COVID-19 pandemic, or at least reduce the impact on life in the future. A group of studies in South Africa argues that the omicron variant is highly contagious and can quickly replace the more pathogenic delta as the dominant variant in various countries (Khan et al., 2021) . And, because it causes mild symptoms, the body produces enough neutralizing antibodies that when we encounter the more lethal variants, there will be no secondary infections. Reducing the pathogenicity of SARS-CoV-2 as well as improving immunity in the population may lead to a reduction in critical cases, resulting in a significantly weakened pandemic. Nonetheless, there is still very limited information on the current status of omicron, such as genomics, transmissibility, vaccine efficacy, treatment, and management. Some researchers hold different attitudes towards its future development because from the current evidence, the infectivity, pathogenicity, and immune escape of omicron have been comprehensively strengthened than previous variants, which may bring more serious consequences.

Another worrying fact is that on January 7, 2022, virologists from the University of Cyprus discovered a new variant with both delta and omicron mutations, and named it deltacron. At present, the variant has been found in countries such as France, the Netherlands and Denmark, and the WHO has also confirmed that deltacron is real and not the result of contamination of laboratory samples (Philippe et al., 2022; Kreier, 2022) . Due to the small number of cases and unknown characteristics of the new variant, it is not classified as a VOC by the WHO for the time being. However, whether deltacron can be both highly pathogenic as the delta variant and highly transmissible as the omicron variant is a matter of global concern. Judging from the current situation, SARS-CoV-2 is still spreading rapidly around the world, the pandemic is far from over, and the future direction of the epidemic is still confusing. Therefore, better knowledge of how mutations affect people in the SARS-CoV-2 genome and its adaptation to the host will help to elucidate the drivers of transmission and evolutionary success. It is worth noting that an article published by Nature on January 12, 2022 elaborates a new perspective on evolution. Existing theories hold that mutations are completely random, and that natural selection determines which mutations survive. However, they found that mutations in plants are somewhat non-random and that essential genes with important biological functions have a much lower mutation frequency (Monroe et al., 2022) . This adaptive mutational bias is a product of evolution and may vary between organisms, a finding that adds a surprising twist to Darwin's theory of evolution by natural selection. Although this theory has not been tested in other species, it may offer another explanation for many of the observations in viral mutations. Since this mutational bias in plants is to protect key genes to ensure survival, we wondered whether high-frequency mutations in key structures and key sites in viruses are also adaptive mutational biases that are forced by survival. As research continues to deepen and the knowledge base expands, we believe that mysteries about viruses and their variants will be revealed one by one. 

Spiking Dependence of SARS-CoV-2 Pathogenicity on TMPRSS2

In Silico Studies of Potency and Safety Assessment of Selected Trial Drugs for the Treatment of COVID-19

Role of Interferon Therapy in Severe COVID-19: The COVIFERON Randomized Controlled

Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model

Evidence of SARS-CoV-2 RNA in an Oropharyngeal Swab Specimen

Extracellular Vimentin is an Attachment Factor That Facilitates SARS-CoV-2 Entry Into Human Endothelial Cells

Effect of Bromhexine on Clinical Outcomes and Mortality in COVID-19 Patients: A Randomized Clinical Trial

Membrane-Anchored Serine Proteases in Health and Disease

The Direct Evidence and Mechanism of Traditional Chinese Medicine Treatment of COVID-19

A Conserved Domain in the Coronavirus Membrane Protein Tail is Important for Virus Assembly

The Species Severe Acute Respiratory Syndrome-Related Coronavirus: Classifying 2019-Ncov and Naming it SARS-CoV-2

Axl as a Mediator of Cellular Growth and Survival

Mortality Outcomes With Hydroxychloroquine and Chloroquine in COVID-19 From an International Collaborative Meta-Analysis of Randomized Trials

Alpha 1 Antitrypsin is an Inhibitor of the SARS-CoV-2-Priming Protease TMPRSS2

A Randomized, Double-Blind, Placebo-Controlled Phase 1 Trial of Inhaled and Intranasal Niclosamide: A Broad Spectrum Antiviral Candidate for Treatment of COVID-19. Lancet Reg. Health Eur. 4, 100084

Mutations in SARS-CoV-2; Consequences in Structure, Function, and Pathogenicity of the Virus

Activation of the SARS Coronavirus Spike Protein via Sequential Proteolytic Cleavage at Two Distinct Sites

Phytochemicals as Potential Therapeutics for SARS-CoV-2-Induced Cardiovascular Complications: Thrombosis and Platelet Perspective

Treatment of Influenza and SARS-CoV-2 Infections via mRNA-Encoded Cas13a in Rodents

Investigation of a COVID-19 Outbreak in Germany Resulting From a Single Travel-Associated Primary Case: A Case Series

Structural and Functional Modelling of SARS-CoV-2 Entry in

Syncytia Formation by SARS-CoV-2-Infected Cells

Structural Basis for Enhanced Infectivity and Immune Evasion of SARS-CoV-2 Variants

The FDA-Approved Drug Ivermectin Inhibits the Replication of SARS-CoV-2 In Vitro

Neuropilin-1 Facilitates SARS-CoV-2 Cell Entry and Infectivity

De Novo Design of Picomolar SARS-CoV-2 Miniprotein Inhibitors

Features, Evaluation, and Treatment of Coronavirus (COVID-19)

SARS-CoV-2 B.1.1.529 (Omicron) Variant-United States

Notes From the Field: Early Evidence of the SARS-CoV-2 B.1.1.529 (Omicron) Variant in Comminity Wastewater -United States

Sex Differences in SARS-CoV-2 Infection Rates and the Potential Link to Prostate Cancer

Risk of Mortality in Patients Infected With SARS-CoV-2 Variant of Concern 202012/1: Matched Cohort Study

Furin Inhibitors Block SARS-CoV-2 Spike Protein Cleavage to Suppress Virus Production and Cytopathic Effects

SARS-CoV-2 Infection Depends on Cellular Heparan Sulfate and ACE2

Tackling COVID-19 With Neutralizing Monoclonal Antibodies

Variant:21K (Omicron)

The SARS-CoV-2 Nucleocapsid Protein is Dynamic, Disordered, and Phase Separates With RNA

Origin and Evolution of Pathogenic Coronaviruses

Neuropilin-1 is a Host Factor for SARS-CoV-2 Infection

Vimentin Diversity in Health and Disease

Japanese Encephalitis Virus Interacts With Vimentin to Facilitate its Entry Into Porcine Kidney Cell Line

SARS-CoV-2 was Already Spreading in France in Late

SARS-CoV-2 Genomic Characterization and Clinical Manifestation of the COVID-19 Outbreak in Uruguay

SARS-CoV-2 and Emerging Variants

High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction With Human Angiotensin Converting Enzyme

The Membrane Protein of SARS-CoV Suppresses NF-kappaB Activation

Analysis of SARS-CoV-2 Vertical Transmission During Pregnancy

Omicron SARS-CoV-2 Variant: What We Know and What We Don't

Increased Mortality of COVID-19 Infected Diabetes Patients: Role of Furin Proteases

Structure of the RNA-Dependent RNA Polymerase From COVID-19 Virus

SARS-CoV-2 Spike Protein Interacts With Multiple Innate Immune Receptors

Early Transmission of SARS-CoV-2 in South Africa

COVID-19-Related Dermatosis in November 2019: Could This Case be Italy's Patient Zero

Tempo and Mode in the Macroevolutionary Reconstruction of Darwinism

Characterization of Neuropilin-1 Structural Features That Confer Binding to Semaphorin 3A and Vascular Endothelial Growth Factor 165

Tissue Distribution of ACE2 Protein, the Functional Receptor for SARS Coronavirus. A First Step in Understanding SARS Pathogenesis

Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions With ACE2

Ready, Set, Fuse! The Coronavirus Spike Protein and Acquisition of Fusion Competence

Systemic and Rapid Restructuring of the Genome: A New Perspective on Punctuated Equilibrium

Rigid Monoclonal Antibodies Improve Detection of SARS-CoV-2 Nucleocapsid Protein

A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung Cells

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

First Case of 2019 Novel Coronavirus in the United States

More That ACE2? NRP1 may Play a Central Role in the Underlying Pathophysiological Mechanism of Olfactory Dysfunction in COVID-19 and its Association With Enhanced Survival

Zika Virus Hijacks Stress Granule Proteins and Modulates the Host Stress Response

Efficacy and Safety of Umifenovir for Coronavirus Disease 2019 (COVID-19): A Systematic Review and Meta-Analysis

Characteristics of SARS-CoV-2 and COVID-19

The In Vitro Antiviral Activity of Lactoferrin Against Common Human Coronaviruses and SARS-CoV-2 is Mediated by Targeting the Heparan Sulfate Co-Receptor

Functional Importance of the D614G Mutation in the SARS-CoV-2 Spike Protein

WHO International Health Regulations Emergency Committee for the COVID-19 Outbreak

Angiotensin-Converting Enzyme 2 and Angiotensin 1-7: Novel Therapeutic Targets

Loss of Furin Cleavage Site Attenuates SARS-CoV-2 Pathogenesis

NETs are a Source of Citrullinated Autoantigens and Stimulate Inflammatory Responses in Rheumatoid Arthritis

Omicron Infection Enhances Neutralizing Immunity Against the Delta Variant

Comparative Genome Analysis of Novel Coronavirus (SARS-CoV-2) From Different Geographical Locations and the Effect of Mutations on Major Target Proteins: An in Silico Insight

Endothelial Targeting of Cowpea Mosaic Virus (CPMV) via Surface Vimentin

Deltacron: The Story of the Variant That Wasn't

SARS-CoV-2 has Been Circulating in Northern Italy Since

Attenuated SARS-CoV-2 Variants With Deletions at the S1/S2 Junction

Structure, Function, and Evolution of Coronavirus Spike Proteins

Molecular Mechanisms of Sex Bias Differences in COVID-19 Mortality

Safety and Effectiveness of SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis

De Novo Design of Potent and Resilient Hace2 Decoys to Neutralize SARS-CoV-2

Vimentin as a Target for the Treatment of COVID-19

Accessory Proteins of SARS-CoV and Other Coronaviruses

The Basis of a More Contagious 501Y.V1 Variant of SARS-COV-2

A Review on Possible Mechanistic Insights of Nitazoxanide for Repurposing in COVID-19

Kinetics of Ribosomal Pausing During Programmed -1 Translational Frameshifting

Intermediate Filaments Play a Pivotal Role in Regulating Cell Architecture and Function

COVID-19 vaccine tracker

The DHODH Inhibitor PTC299 Arrests SARS-CoV-2 Replication and Suppresses Induction of Inflammatory Cytokines

The SARS-CoV-2 Nucleocapsid Phosphoprotein Forms Mutually Exclusive Condensates With RNA and the Membrane-Associated M Protein

Genomic Characterisation and Epidemiology of 2019 Novel Coronavirus: Implications for Virus Origins and Receptor Binding

Characterization of a Highly Conserved Domain Within the Severe Acute Respiratory Syndrome Coronavirus Spike Protein S2 Domain With Characteristics of a Viral Fusion Peptide

SARS-CoV-2 Mutations: The Biological Trackway Towards Viral Fitness

Enhanced Isolation of SARS-CoV-2 by TMPRSS2-Expressing Cells

The Coronavirus Nucleocapsid is a Multifunctional Protein

COVID-19 Pandemic: Insights Into Structure, Function, and Hace2 Receptor Recognition by SARS-CoV-2

Genomic Variations in the Structural Proteins of SARS-CoV-2 and Their Deleterious Impact on Pathogenesis: A

Body Fluids may Contribute to Human-to-Human Transmission of Severe Acute Respiratory Syndrome Coronavirus 2: Evidence and Practical Experience

The Pivotal Role of TMPRSS2 in Coronavirus Disease 2019 and Prostate Cancer

Mutation Bias Reflects Natural Selection in Arabidopsis Thaliana

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human Ace2

Genotype and Phenotype of COVID-19: Their Roles in Pathogenesis

A Structural Analysis of M Protein in Coronavirus Assembly and Morphology

Severe Acute Respiratory Syndrome Coronavirus Envelope Protein Ion Channel Activity Promotes Virus Fitness and Pathogenesis

Viroporins: Structure and Biological Functions

Axl, a Transforming Gene Isolated From Primary Human Myeloid Leukemia Cells, Encodes a Novel Receptor Tyrosine Kinase

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Envelope Glycoprotein Interactions in Coronavirus Assembly

Characterization of Spike Glycoprotein of SARS-CoV-2 on Virus Entry and its Immune Cross-Reactivity With SARS-CoV

Furin Cleavage of SARS-CoV-2 Spike Promotes But is Not Essential for Infection and Cell-Cell Fusion

Renin-Angiotensin-Aldosterone (RAAS): The Ubiquitous System for Homeostasis and Pathologies

Structures of the SARS-CoV-2 Nucleocapsid and Their Perspectives for Drug Design

Culture and Identification of a "Deltamicron" SARS-CoV-2 in a Three Cases Cluster in Southern France. medRxiv (medRxiv)

The Role of Programmed-1 Ribosomal Frameshifting in Coronavirus Propagation

Spike Mutation D614G Alters SARS-CoV-2 Fitness

The Variant Gambit: COVID-19's Next Move

The Functional Consequences of the Novel Ribosomal Pausing Site in SARS-CoV-2 Spike Glycoprotein RNA

Using the Spike Protein Feature to Predict Infection Risk and Monitor the Evolutionary Dynamic of Coronavirus

SARS-CoV-2 RNA in Wastewater Anticipated COVID-19 Occurrence in a Low Prevalence Area

Convalescent Plasma in Covid-19: Possible Mechanisms of Action

An Update of Anti-Viral Treatment of COVID-19. Turk

Identification and Characterization of the Putative Fusion Peptide of the Severe Acute Respiratory Syndrome-Associated Coronavirus Spike Protein

Competing Protein-RNA Interaction Networks Control Multiphase Intracellular Organization

The ACE2/Angiotensin

Structural Insight Into the Role of Novel SARS-CoV-2 E Protein: A Potential Target for Vaccine Development and Other Therapeutic Strategies

SARS-CoV-2 Variants With Mutations at the S1/S2 Cleavage Site are Generated In Vitro During Propagation in TMPRSS2-Deficient Cells

Vimentin Modulates Infectious Internalization of Human Papillomavirus 16 Pseudovirions

Role of Neuropilin-2 in the Immune System

Coronavirus Envelope Protein: Current Knowledge

Structural Basis of Receptor Recognition by SARS-CoV-2

High-Resolution Analysis and Functional Mapping of

Cleavage Sites and Substrate Proteins of Furin in the Human Proteome

One Severe Acute Respiratory Syndrome Coronavirus Protein Complex Integrates Processive RNA Polymerase and Exonuclease Activities

The Role of Cell Surface Sialic Acids for SARS-CoV-2 Infection

Basic Amino Acid Substitution at Residue 367 of the Envelope Protein of Tembusu Virus Plays a Critical Role in Pathogenesis

Extracellular Vimentin as a Target Against SARS-CoV-2 Host Cell Invasion

Activation of NF-kb and Induction of Proinflammatory Cytokine Expressions Mediated by ORF7a Protein of SARS-CoV-2

Convergent Use of Phosphatidic Acid for Hepatitis C Virus and SARS-CoV

Replication Organelle Formation

Association of Autoimmunity and Cancer: An Emphasis on Proteolytic Enzymes

Coronavirus Membrane Fusion Mechanism Offers a Potential Target for Antiviral Development

Abnormal Coagulation Parameters are Associated With Poor Prognosis in Patients With Novel Coronavirus Pneumonia

Note From the Editors: World Health Organization Declares Novel Coronavirus (2019-Ncov) Sixth Public Health Emergency of International Concern

Detection of a SARS-CoV-2 Variant of Concern in South Africa

Dc/L-SIGN Recognition of Spike Glycoprotein Promotes SARS-CoV-2 Trans-Infection and can be Inhibited by a Glycomimetic Antagonist

NETosis Proceeds by Cytoskeleton and Endomembrane Disassembly and PAD4-Mediated Chromatin Decondensation and Nuclear Envelope Rupture

Furin at the Cutting Edge: From Protein Traffic to Embryogenesis and Disease

Gene of the Month: TMPRSS2 (Transmembrane Serine Protease 2)

A Human Homolog of Angiotensin-Converting Enzyme. Cloning and Functional Expression as a Captopril-Insensitive Carboxypeptidase

Aerosol and Surface Stability of SARS-CoV-2 as Compared With SARS-CoV-1

Emergence of Genomic Diversity and Recurrent Mutations in SARS-CoV-2

Endothelial Cell Infection and Endotheliitis in COVID-19

Omicron Emerges

The Coronavirus Nucleocapsid Protein is Dynamically Associated With the Replication-Transcription Complexes

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

CD147-Spike Protein is a Novel Route for SARS-CoV-2 Infection to Host Cells

Neuropilin-1 Aggravates Liver Cirrhosis by Promoting Angiogenesis via VEGFR2-Dependent PI3K/Akt Pathway in Hepatic Sinusoidal Endothelial Cells

AXL is a Candidate Receptor for SARS-CoV-2 That Promotes Infection of Pulmonary and Bronchial Epithelial Cells

SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development

Site-Specific Glycan Analysis of the SARS-CoV-2 Spike

Tracking SARS-CoV-2 Variants

Cryo-EM Structure of the 2019-Ncov Spike in the Prefusion Conformation

Inhibition of SARS-CoV-2 (Previously 2019-Ncov) Infection by a Highly Potent Pan-Coronavirus Fusion Inhibitor Targeting its Spike Protein That Harbors a High Capacity to Mediate Membrane Fusion

Superficial Vimentin Mediates DENV-2 Infection of

Structural Basis for the Recognition of SARS-CoV-2 by Full-Length Human ACE2

Role of the Coronavirus E Viroporin Protein Transmembrane Domain in Virus Assembly

The Proteins of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS CoV-2 or N-COV19), the Cause of COVID-19

Surface Vimentin is Critical for the Cell Entry of SARS-CoV

Biochemical Features and Mutations of Key Proteins in SARS-CoV-2 and Their Impacts on RNA Therapeutics

Heparan Sulfate Assists SARS-CoV-2 in Cell Entry and can be Targeted by Approved Drugs In Vitro

Analysis of Genomic Characteristics and Transmission Routes of Patients With Confirmed SARS-CoV-2 in Southern California During the Early Stage of the US COVID-19 Pandemic

Molecular Mechanism of Interaction Between SARS-CoV-2 and Host Cells and Interventional Therapy

Entry, Egress and Vertical Transmission of SARS-CoV-2

GCG Inhibits SARS-CoV-2 Replication by Disrupting the Liquid Phase Condensation of its Nucleocapsid Protein

Protease Inhibitors Targeting Coronavirus and Filovirus Entry

A Pneumonia Outbreak Associated With a New Coronavirus of Probable Bat Origin

A Novel Coronavirus From Patients With Pneumonia in China

SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets Across Tissues

Lost in Deletion: The Enigmatic ORF8 Protein of SARS-CoV-2

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.